Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SRZN | US
0.17
0.53%
Healthcare
Biotechnology
30/06/2024
15/04/2026
32.02
31.68
33.22
30.36
Surrozen Inc. a clinical stage biotechnology company discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas including diseases of the intestine liver retina cornea lung kidney cochlea skin pancreas and central nervous system. Its products in pipeline include SZN-043 a hepatocyte-specific R-spondin mimetic bispecific fusion protein which is in Phase 1b clinical trial for the treatment of severe liver diseases including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326 a bi-specific antibody which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease Frizzled and LRP receptors. The company also develops SZN-413 a Fzd4 targeted bi-specific antibody which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research develop and commercialize Fzd4 bi-specific antibodies. Surrozen Inc. was founded in 2015 and is based in South San Francisco California.
View LessPositive Momentum
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
66.7%1 month
63.0%3 months
72.7%6 months
82.0%-
-
5.22
0.36
0.05
0.71
-
-
-35.84M
102.65M
102.65M
-
-
-
-
-174.90
4.24
2.09
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
8.11
Range1M
9.59
Range3M
15.24
Rel. volume
2.65
Price X volume
9.17M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Dermira Inc | DERM | Biotechnology | 5.3 | 109.85M | 0.76% | 47.08 | 201.92% |
| Cellectar Biosciences Inc | CLRB | Biotechnology | 3.04 | 108.98M | 3.05% | n/a | 2.10% |
| Aldeyra Therapeutics Inc | ALDX | Biotechnology | 1.83 | 108.74M | 2.23% | n/a | 15.90% |
| Common Stock | TARA | Biotechnology | 5.21 | 107.48M | 1.56% | n/a | 5.41% |
| Agenus Inc | AGEN | Biotechnology | 4.83 | 104.19M | 2.33% | n/a | -170.56% |
| Gossamer Bio Inc | GOSS | Biotechnology | 0.4509 | 102.01M | 4.47% | n/a | 243.93% |
| Pyxis Oncology Inc. Common Stock | PYXS | Biotechnology | 1.71 | 101.61M | 0.59% | n/a | 12.29% |
| IN8bio Inc. Common Stock | INAB | Biotechnology | 1.4 | 101.57M | 1.45% | n/a | 43.30% |
| GENELUX CORP | GNLX | Biotechnology | 2.84 | 98.08M | 7.58% | n/a | 5.86% |
| Anthem Inc. CORP UNIT 050118 | ANTX | Biotechnology | 3.26 | 97.29M | 9.40% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.77 | 99.85M | 1.05% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.09 | 99.20M | 0.50% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.795 | 73.85M | -1.54% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.32 | 59.96M | -7.78% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.72 | 20.90M | -6.98% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6299 | 12.17M | 1.11% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.6947 | 10.15M | -23.66% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.3631 | 3.48M | 3.27% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.231 | 2.20M | 7.49% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.74 | 958.74K | -6.95% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.71 | 0.53 | Expensive |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 5.22 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 72.71 | 72.80 | Par |
| Debt to Equity | 0.36 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 102.65M | 3.66B | Emerging |